These Phase 2 trial results reported in Neuropsychopharmacology are the first statistically significantly positive data in a large randomized trial for cognitive impairment in schizophrenia,” said Dana C. Hilt, M.D., Senior Vice President, Clinical Development and Chief Medical Officer of FORUM. “Encenicline had positive effects in a number of cognitive and functional endpoints, and is the first drug candidate to demonstrate improvement using the MATRICS Consensus Cognitive Battery (MCCB), developed by the MATRICS project in conjunction with the National Institute of Mental Health and the U.S. Food and Drug Administration (FDA).
Boy, I’m really putting myself out there, but I’m struggling to keep up with all of this. It seems like there are so many medications making it to these later phases but I’m afraid I’m a little lost. Can somebody explain the significance of MCCB. I was on the MHS webpage but am looking for some “dumbed-down” supplemental info. Thanks in advance. My kid is nineteen, so these trials seem encouraging and give me hope…
